338 results on '"Larché, M"'
Search Results
2. Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: the Ontario Best Practices Research Initiative—a rheumatoid arthritis cohort
3. Value of 111In-Pentetreotide scintigraphy and 18F-FDG PET for clinical prognosis of patients with neuroendocrine neoplasms
4. Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin‐induced thrombocytopenia
5. Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype
6. Organic solvent exposure and systemic sclerosis: A retrospective cohort study based on the Canadian Scleroderma Research Group registry
7. The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study
8. Elevated CD27-IgD- B cells in Post-Acute COVID-19 Sequalae Patients with Rheumatological Symptoms
9. Document de consensus WAO–ARIA–GA2LEN sur le diagnostic allergologique moléculaire
10. Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35
11. The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients
12. Geographical distribution of systemic sclerosis in Canada: An ecologic study based on the Canadian Scleroderma Research Group
13. POS0111 MORE METICULOUSLY FOLLOWING TREAT-TO-TARGET IN RA DOES NOT LEAD TO LESS RADIOGRAPHIC PROGRESSION: A LONGITUDINAL ANALYSIS IN BIODAM
14. Treatment with anti-cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity
15. Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis
16. One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence
17. Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis
18. T regulatory cell phenotypes in peripheral blood and bronchoalveolar lavage from non-asthmatic and asthmatic subjects
19. The Canadian Healthy Infant Longitudinal Development (CHILD) Study: examining developmental origins of allergy and asthma
20. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects
21. Comprehensive metabolomics identifies the alarmin uric acid as a critical signal for the induction of peanut allergy
22. T cell-mediated induction of thymic stromal lymphopoietin in differentiated human primary bronchial epithelial cells
23. Damage Trajectories in Systemic Sclerosis Using Group‐BasedTrajectory Modeling
24. Lasting changes to circulating leukocytes in people with mild SARS-CoV-2 infections
25. Indirect Recognition of T-Cell Epitopes Derived from the α3 and Transmembrane Domain of HLA-A2
26. OX40L blockade and allergen-induced airway responses in subjects with mild asthma
27. Cytokine responses of peripheral blood mononuclear cells to allergen do not identify asthma or asthma phenotypes
28. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy
29. Immunotherapy with peptides
30. Development and Preliminary Clinical Evaluation of a Peptide Immunotherapy Vaccine for Cat Allergy: 843
31. Induction of Thymic Stromal Lymphopoietin (TSLP) in Airway Epithelium by Recombinant Allergens: 474
32. Of cats and men: immunodominance and the role of HLA-DP/DQ
33. Airway expression of calcitonin gene-related peptide in T-cell peptide-induced late asthmatic reactions in atopics
34. Peptide immunotherapy for allergic diseases
35. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy
36. The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a randomized feasibility trial
37. Peptide therapy in allergic disease: IS42
38. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects
39. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-Ω+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects
40. Acute cat allergen challenge recruits T1/ST2+ but not Tim 3+ CD4+ cells to lungs of DR1 transgenic mice: 6.13
41. Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double-blind placebo-controlled study
42. Therapeutic tolerance in a HLA DR1-transgenic murine model of cat allergen sensitivity
43. Anti-T-cell strategies in the treatment of allergic disease
44. Changes in interferon-γ production following specific allergen immunotherapy: biology vs methodology
45. BLOOD EOSINOPHILS FROM ATOPIC DONORS EXPRESS mRNA FOR THE α,β AND γ SUBUNITS OF THE HIGH AFFINITY IgE RECEPTOR (FcϵRI) AND INTRACELLULAR, BUT NO CELL SURFACE, α SUBUNIT PROTEIN
46. CYTOKINE RESPONSES IN ATOPIC ASTHMATICS TO DISTINCT REGIONS OF A SINGLE ALLERGEN: COMPARISON WITH ATOPIC NON-ASTHMATIC AND NON-ATOPIC CONTROLS
47. ATTENUATION OF BRONCHIAL AND CUTANEOUS ALLERGIC LATE PHASE RESPONSES BY ALLERGEN-DERIVED PEPTIDES
48. Allergen isoforms for immunotherapy: diversity, degeneracy and promiscuity
49. Mammalian target of rapamycin is activated in the kidneys of patients with scleroderma renal crisis
50. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.